Tesamorelin vs Leuphasyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Leuphasyl
Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Leuphasyl |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Mimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Topical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Topical application to expression lines. Best results with consistent twice-daily use over 8+ weeks. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Very well-tolerated topically. No significant adverse effects reported at cosmetic concentrations. |
| Best For |